197 related articles for article (PubMed ID: 30118782)
41. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
42. Association Study of the Complement Component C4 Gene in Tardive Dyskinesia.
Zai CC; Tiwari AK; Zai GC; Freeman N; Pouget JG; Greco J; Tampakeras M; Shaikh SA; Herbert D; Emmerson H; Cheema SY; Braganza N; Müller DJ; Voineskos AN; Remington G; Kennedy JL
Front Pharmacol; 2019; 10():1339. PubMed ID: 31849639
[TBL] [Abstract][Full Text] [Related]
43. Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia.
Fedorenko OY; Loonen AJ; Lang F; Toshchakova VA; Boyarko EG; Semke AV; Bokhan NA; Govorin NV; Aftanas LI; Ivanova SA
Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25548108
[TBL] [Abstract][Full Text] [Related]
44. Genome wide study of tardive dyskinesia in schizophrenia.
Lim K; Lam M; Zai C; Tay J; Karlsson N; Deshpande SN; Thelma BK; Ozaki N; Inada T; Sim K; Chong SA; Lencz T; Liu J; Lee J
Transl Psychiatry; 2021 Jun; 11(1):351. PubMed ID: 34103471
[TBL] [Abstract][Full Text] [Related]
45. Tardive dyskinesia: Who gets it and why.
Frei K
Parkinsonism Relat Disord; 2019 Feb; 59():151-154. PubMed ID: 30522959
[TBL] [Abstract][Full Text] [Related]
46. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.
Cho CH; Lee HJ
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():207-13. PubMed ID: 23123399
[TBL] [Abstract][Full Text] [Related]
47. Clinical management of tardive dyskinesia: Five steps to success.
Citrome L
J Neurol Sci; 2017 Dec; 383():199-204. PubMed ID: 29246613
[TBL] [Abstract][Full Text] [Related]
48. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia.
Lee HJ; Kang SG; Choi JE; Paik JW; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
Neuropsychobiology; 2007; 55(1):47-51. PubMed ID: 17556853
[TBL] [Abstract][Full Text] [Related]
49. No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia.
Lee HJ; Kang SG; Paik JW; Lee MS; Cho BH; Park YM; Kim W; Choi JE; Jung IK; Kim L; Lee MS
Hum Psychopharmacol; 2007 Dec; 22(8):501-4. PubMed ID: 17726725
[TBL] [Abstract][Full Text] [Related]
50. Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment.
Lattuada E; Cavallaro R; Serretti A; Lorenzi C; Smeraldi E
Int J Neuropsychopharmacol; 2004 Dec; 7(4):489-93. PubMed ID: 15383158
[TBL] [Abstract][Full Text] [Related]
51. Antipsychotic-induced movement disorders in long-stay psychiatric patients and 45 tag SNPs in 7 candidate genes: a prospective study.
Bakker PR; Al Hadithy AF; Amin N; van Duijn CM; van Os J; van Harten PN
PLoS One; 2012; 7(12):e50970. PubMed ID: 23226551
[TBL] [Abstract][Full Text] [Related]
52. Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia.
Lai IC; Wang YC; Lin CC; Bai YM; Liao DL; Yu SC; Lin CY; Chen JY; Liou YJ
J Neural Transm (Vienna); 2005 Aug; 112(8):1107-13. PubMed ID: 15583953
[TBL] [Abstract][Full Text] [Related]
53. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism.
Tiwari AK; Deshpande SN; Rao AR; Bhatia T; Mukit SR; Shriharsh V; Lerer B; Nimagaonkar VL; Thelma BK
Pharmacogenomics J; 2005; 5(1):60-9. PubMed ID: 15505641
[TBL] [Abstract][Full Text] [Related]
54. Pharmacological treatment of tardive dyskinesia: recent developments.
Caroff SN; Campbell EC; Carroll B
Expert Rev Neurother; 2017 Sep; 17(9):871-881. PubMed ID: 28727483
[TBL] [Abstract][Full Text] [Related]
55. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients.
Zai CC; Tiwari AK; Basile V; De Luca V; Müller DJ; King N; Voineskos AN; Remington G; Meltzer HY; Lieberman JA; Potkin SG; Kennedy JL
Pharmacogenomics J; 2009 Jun; 9(3):168-74. PubMed ID: 19238168
[TBL] [Abstract][Full Text] [Related]
56. Association study of MiRSNPs with schizophrenia, tardive dyskinesia and cognition.
John J; Bhatia T; Kukshal P; Chandna P; Nimgaonkar VL; Deshpande SN; Thelma BK
Schizophr Res; 2016 Jul; 174(1-3):29-34. PubMed ID: 27106592
[TBL] [Abstract][Full Text] [Related]
57. Quantitative DNA Methylation Analysis of DLGAP2 Gene using Pyrosequencing in Schizophrenia with Tardive Dyskinesia: A Linear Mixed Model Approach.
Li Y; Wang K; Zhang P; Huang J; An H; Wang N; De Yang F; Wang Z; Tan S; Chen S; Tan Y
Sci Rep; 2018 Nov; 8(1):17466. PubMed ID: 30504779
[TBL] [Abstract][Full Text] [Related]
58. Pyrosequencing analysis of IRS1 methylation levels in schizophrenia with tardive dyskinesia.
Li Y; Wang K; Zhang P; Huang J; Liu Y; Wang Z; Lu Y; Tan S; Yang F; Tan Y
Mol Med Rep; 2020 Apr; 21(4):1702-1708. PubMed ID: 32319643
[TBL] [Abstract][Full Text] [Related]
59. There is no evidence for an association between the serotonin receptor 3A gene C178T polymorphism and tardive dyskinesia in Korean schizophrenia patients.
Kang SG; Lee HJ; Yoon HK; Cho SN; Park YM; Kim L
Nord J Psychiatry; 2013 Jun; 67(3):214-8. PubMed ID: 23126479
[TBL] [Abstract][Full Text] [Related]
60. [Genome-wide association analyses for neuroleptic-induced tardive dyskinesia].
Arinami T; Inada T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Aug; 31(4):155-62. PubMed ID: 21941849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
